在干眼病评估和管理研究中，基线时系统 ω-3 脂肪酸水平与中重度干眼病体征和症状的相关性。
Associations Between Systemic Omega-3 Fatty Acid Levels With Moderate-to-Severe Dry Eye Disease Signs and Symptoms at Baseline in the Dry Eye Assessment and Management Study.
机构信息
Ophthalmology (E.J.K., K.Y.K., P.A.A.), Icahn School of Medicine at Mount Sinai, New York, NY; Private Practice (M.M.H.), Azusa, CA; Ophthalmology (G.-S.Y., M.G.M.), University of Pennsylvania, Philadelphia, PA; Clinical Research Center (M.C.L.), University of California, Berkeley, CA; Program in Integrative Nutrition & Complex Diseases (R.S.C.), Texas A&M University, College Station, TX; Kennedy Krieger Institute (R.J., A.M.), Baltimore, MD; and Ophthalmology (P.A.A.), University of Tennessee, Memphis, TN.
出版信息
Eye Contact Lens. 2021 Jan 1;47(1):2-7. doi: 10.1097/ICL.0000000000000687.
PURPOSE
Omega-3 (n-3) fatty acid supplementation is used to treat systemic inflammatory diseases, but the role of n-3 in the pathophysiology and therapy of dry eye disease (DED) is not definitive. We evaluated the relationship of systemic n-3 levels with signs and symptoms at baseline in the Dry Eye Assessment and Management (DREAM) Study.
METHODS
Blood samples from participants at baseline were analyzed for n-3 and n-6, measured as relative percentage by weight among all fatty acids in erythrocytes. Symptoms were evaluated using the Ocular Surface Disease Index. Signs including conjunctival staining, corneal staining, tear breakup time (TBUT), and Schirmer's test with anesthesia were also evaluated.
RESULTS
There was no correlation between the systemic n-3 levels and DED symptoms. When the associations with signs of DED were assessed, lower DHA levels were associated with higher conjunctival staining, with mean scores of 3.31, 2.96, and 2.82 for low, medium, and high levels of DHA, respectively (linear trend P=0.007). None of the other signs were associated with DHA or the other measures of n-3.
CONCLUSION
Previous studies have found varying results on the role of n-3 supplementation with the signs and symptoms of DED. Among patients with DED enrolled in the DREAM Study, lower systemic n-3 levels were not associated with worse symptoms and most signs of DED.
目的
ω-3（n-3）脂肪酸补充剂用于治疗全身性炎症性疾病，但 n-3 在干眼疾病（DED）的病理生理学和治疗中的作用尚不确定。我们评估了系统性 n-3 水平与 DREAM 研究中基线时的体征和症状的关系。
方法
对基线期参与者的血液样本进行 n-3 和 n-6 分析，以红细胞中所有脂肪酸的重量百分比表示。使用眼表面疾病指数评估症状。还评估了体征，包括结膜染色、角膜染色、泪膜破裂时间（TBUT）和麻醉下的 Schirmer 测试。
结果
系统性 n-3 水平与 DED 症状之间无相关性。当评估与 DED 体征的关联时，较低的 DHA 水平与较高的结膜染色相关，DHA 水平低、中、高的平均得分分别为 3.31、2.96 和 2.82（线性趋势 P=0.007）。DHA 或其他 n-3 测量值与其他任何体征均无关联。
结论
先前的研究对 n-3 补充剂与 DED 的体征和症状的作用得出了不同的结果。在 DREAM 研究中招募的 DED 患者中，较低的系统性 n-3 水平与更严重的症状和大多数 DED 体征无关。
Zotero 插件